EVE Health Group Limited (ASX:EVE)

Market Cap	7.69M +45.8%
Revenue (ttm)	1.36M -34.2%
Net Income	-1.62M
EPS	-0.01
Shares Out	349.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,174,748
Average Volume	558,998
Open	0.0200
Previous Close	0.0200
Day's Range	0.0200 - 0.0220
52-Week Range	0.0170 - 0.0400
Beta	0.29
RSI	59.96
Earnings Date	May 28, 2026

About EVE Health Group

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2003
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EVE

Financial Performance

In fiscal year 2025, EVE Health Group's revenue was 1.73 million, a decrease of -18.70% compared to the previous year's 2.13 million. Losses were -1.58 million, -16.89% less than in 2024.